Aktienanalyse zu Alpha Cognition Inc (ACOG)ACOGAlpha Cognition Inc

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis. It operates in the Healthcare sector.

Alpha Cognition Inc (ACOG) appears to be a good buy right now due to its recent positive momentum and strong analyst support. The current price of $9.04 is significantly lower than the average analyst price target of $21, suggesting a potential upside of approximately 132%. Additionally, the company's gross margin has improved to 93.58% in Q2 2026, indicating strong profitability potential despite current losses. However, investors should be cautious of the recent revenue misses, including a shortfall of $0.09 million in Q1 2026, which could impact short-term performance.